CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Lyme disease - Evidence
Supporting evidence
- CKS has considered the evidence on antibiotic treatment for adults and children with erythema migrans.
- CKS has not considered the evidence on the treatment of people with neurological, rheumatological, cardiac, or other skin involvement because these people are likely to require specialist assessment (to exclude other causes of symptoms and signs), specialist investigations (such as lumbar puncture), or secondary care management (such as continuous monitoring for people with cardiac involvement, or intravenous antibiotics).
- Systematic reviews and subsequent randomized controlled trials have been considered for inclusion.
© NHS Institute for Innovation and Improvement